Genvor is an early-stage agricultural biotechnology company developing peptide-based crop protection and enhancement products, with no revenue yet and operations still in the R&D phase. Genvor's core technology is antimicrobial peptides (AMPs) — short amino acid chains that kill fungal, bacterial, and viral pathogens by physically rupturing cell walls. Because AMPs work through a mechanical disruption mechanism rather than a biochemical one, pathogens are unlikely to develop resistance, and AMPs are biodegradable and leave no crop residue. Genvor is developing AMPs in two delivery formats: transgenic seed traits, where crops are genetically engineered to express AMPs internally, and foliar sprays applied directly to crops. Genvor's lead validated product is transgenic corn expressing peptide AGM182, developed in partnership with the USDA. Genvor's primary IP asset is the BioCypher Algorithm, an AI-driven peptide discovery platform trained on over 9,000 proprietary synthetic AMPs, which Genvor claims can screen 100,000 peptide candidates computationally. Beyond crop protection, Genvor is also developing nutritionally enhanced peptides to increase protein expression in feed crops. Genvor's business model is capital-light licensing: rather than manufacturing or selling products directly, Genvor intends to license its peptide IP to established agricultural input companies, earning licensing fees and royalties while partners handle manufacturing, regulatory approval, and distribution. Genvor currently operates with two full-time employees and a small wet lab in Woodland, California, and leverages a cooperative R&D agreement with the USDA to access labs and field trials at low cost.